Latest News

Print

UCLA Jonsson Comprehensive Cancer Center physicians, scientists to present on latest cancer research advancements at ASCO annual meeting

The 54th Annual Meeting of the American Society of Clinical Oncology is on June 1 - 5 in Chicago, Illinois

Post Date:May 21, 2018 9:00 AM

Scientists at the UCLA Jonsson Comprehensive Cancer Center (JCCC) will be presenting on the latest advancements in clinical cancer research, alternative treatment options for late-stage cancers and the newest developments in immunotherapy at the Annual Meeting of the American Society of Clinical Oncology. The annual event takes place at the McCormick Convention Center in Chicago from June 1 to June 5.

JCCC researchers will highlight UCLA-led study results focused on new treatment options for metastatic breast cancer, review benefits of PET/CT guided salvage therapy for prostate cancer and reveal new combination anti-PD1 immunotherapies for melanoma and other cancers.

The year’s theme for the conference is Delivering Discoveries: Expanding the Reach of Precision Medicine and will bring together more than 32,000 scientists, clinicians, advocates and industry leaders from institutions around the world to discuss significant advances in cancer research.

More than 30 abstracts, sessions and events at ASCO 2018 will feature members of JCCC. Below are UCLA-led oral abstracts, presentations and other events where JCCC researchers are speaking or appearing.

For the complete ASCO 2018 Annual Meeting program, please visit their iPlanner.

Oral abstracts

Breast Cancer—Metastatic

Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.

Abstract 1000
Faculty: Dennis J. Slamon, MD, PhD, UCLA Jonsson Comprehensive Cancer Center
Sunday, June 3, 8:00 a.m. to 11:00 a.m.
Location: Hall D2

Genitourinary (Prostate Cancer)

Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.

Abstract 5001
Faculty: Wolfgang Fendler, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA
Monday, June 4, 3:00 p.m. to 6:00 p.m.
Location: Hall D1

Pediatric Oncology II

Defining the Risks of Secondary Malignancies in Childhood Cancer Survivors

Discussing Abstract(s): 10509, 10510 & 10511
Faculty: Patricia A. Ganz, M.D., F.A.S.C.O, Jonsson Comprehensive Cancer Center
Sunday, June 3, 8:36 a.m. to 8:48 a.m.
Location: S504

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Novel Strategies for HER2-Driven Tumors

Discussing Abstract(s): 2500, 2501 & 2502
Faculty: Dennis J. Slamon, M.D., Ph.D., UCLA Jonsson Comprehensive Cancer Center
Friday, June 1, 3:20 p.m. to 3:30 p.m.
Location: S406

Educational sessions

Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies

East Meets West: Role of Complementary Treatments

Faculty: Ka-Kit Hui, M.D., F.A.C.P, David Geffen School of Medicine at UCLA, member of the UCLA Jonsson Comprehensive Cancer Center
Friday, June 1, 1:00 p.m. to 2:15 p.m.
Location: E451

Tweets, Posts, and Snaps: Starting Down the Social Media Pathway

Striking the Right Tone: Optimizing the Use of Social Media During Conferences

Faculty: Deanna J. Attai, M.D., David Geffen School of Medicine at UCLA
Saturday, June 2, 8:00 a.m. to 9:15 a.m.
Location: S504

Meet the professor session

Optimizing Therapy for ER-Positive Metastatic Breast Cancer

Chair: Sara Hurvitz, M.D., Jonsson Comprehensive Cancer Center
Monday, June 4, 1:15 p.m. to 2:30 p.m.
Location: E253c

Poster sessions

Lung Cancer—Non-Small Cell Metastatic

A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.

Poster Board: #337 • Abstract 9014
Faculty: Aaron Elliott Lisberg, M.D., UCLA
Sunday, June 3, 8:00 a.m. to 11:30 a.m.
Location: Hall A

* Being discussed at the Poster Discussion Session on Sunday, June 3, 2018, 11:30 AM - 12:45 PM, in Arie Crown Theater

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).

Poster Board: #124 • Abstract 8518
Faculty: Jonathan Goldman, M.D., UCLA Jonsson Comprehensive Cancer Center
Sunday, June 3, 8:00 a.m. to 11:30 a.m.
Location: Hall A

* Being discussed at the Poster Discussion Session on Sunday, June 3, 2018, 4:45 PM - 6:00 PM, in Arie Crown Theater

Lung Cancer—Non-Small Cell Metastatic

A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.

Poster Board: #337 • Abstract 9014
Faculty: Aaron Elliott Lisberg, M.D., UCLA
Sunday, June 3, 8:00 a.m. to 11:30 a.m.
Location: Hall A

*Being discussed at the Poster Discussion Session on Sunday, June 3, 2018, 11:30 AM - 12:45 PM, in Arie Crown Theater

Tumor Biology

Role of CD4 cells in the complete anti-tumor response to PD1 blockade in a syngeneic murine melanoma model with activated WNT signaling.

Poster Board: #126 • Abstract 12013
Faculty: Siwen Hu-Lieskovan, M.D, Ph.D., UCLA's Jonsson Comprehensive Cancer Center
Monday, June 4, 1:15 p.m. to 4:45 p.m.
Location: Hall A

* Being discussed at the Poster Discussion Session on Monday, June 4, 2018, 4:45 PM - 6:00 PM, in S406

Melanoma/Skin Cancers

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.

Poster Board: #340 • Abstract 9513
Faculty: Antoni Ribas, M.D., Ph.D., UCLA Jonsson Comprehensive Cancer Center
Monday, June 4, 1:15 p.m. to 4:45 p.m.

*Being discussed at the Poster Discussion Session on Monday, June 4, 2018, 4:45 PM - 6:00 PM, in E451

Return to full list >>